Brief: Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint
09/01/2026 13:58
Jan 9 (Reuters) - PDS Biotechnology Corp PDSB.O: PDS BIOTECH ANNOUNCES FDA ALIGNMENT ON USE OF PROGRESSION FREE SURVIVAL (PFS) AS PRIMARY ENDPOINT PDS BIOTECHNOLOGY CORP - AMENDMENT CHANGES PFS TO PRIMARY ENDPOINT FOR ACCELERATED APPROVAL PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL REMAINS PRIMARY ENDPOINT FOR FULL APPROVAL Source text: ID:nGNX6rC23C Further company coverage: PDSB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing